PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-7.52%
Both companies show negative ROE. Martin Whitman would check if the entire market segment is distressed.
-7.08%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
-7.57%
Both companies show negative ROCE. Martin Whitman would investigate if external factors hamper profitability.
100.00%
Similar gross margin to TRAW's 100.00%. Walter Schloss would check if both companies have comparable cost structures.
-863.67%
Both companies are negative at the operating level. Martin Whitman would see if the entire niche faces fundamental challenges.
-855.31%
Both companies run at a net loss. Martin Whitman would see if broader market headwinds persist.